Alyeska Investment Group L.P. Boosts Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Alyeska Investment Group increased its Thermo Fisher stake by 201% in the second quarter, adding 251,127 shares to own 376,071 shares valued at approximately $188.5 million. Institutional investors collectively own 89.23% of TMO.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $619.41. Recent targets range from $520 to $650.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in EPS and $11.99 billion in revenue, with revenue up 10.5% year over year. The company also declared a quarterly dividend of $0.47 per share, while insiders have sold $44.1 million of stock over the past 90 days.

Alyeska Investment Group L.P. grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 201.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 376,071 shares of the medical research company's stock after buying an additional 251,127 shares during the period. Alyeska Investment Group L.P. owned 0.10% of Thermo Fisher Scientific worth $188,547,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in TMO. Legacy Wealth Managment LLC ID grew its position in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after acquiring an additional 22 shares during the period. Kilter Group LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $25,000. Allied Private Wealth LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $26,000. High Note Wealth LLC raised its holdings in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after buying an additional 29 shares during the period. Finally, Swiss RE Ltd. acquired a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on TMO shares. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Barclays upped their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating on the stock in a research report on Friday, May 8th. Sanford C. Bernstein initiated coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a "market perform" rating and a $520.00 target price on the stock. Finally, Wolfe Research assumed coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $619.41.

Thermo Fisher Scientific Stock Down 1.4%

Shares of Thermo Fisher Scientific stock opened at $621.87 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $647.00. The company has a market capitalization of $229.94 billion, a PE ratio of 33.45, a P/E/G ratio of 2.53 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The business has a 50-day moving average of $558.64 and a 200-day moving average of $512.08.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter in the previous year, the firm posted $4.28 earnings per share. The company's revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.11%.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Michael D. Shafer sold 25,500 shares of the business's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares of the company's stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the company's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares in the company, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 73,768 shares of company stock worth $44,122,820 in the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source